PHILADELPHIA and BALTIMORE, May 06, 2021 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced ...

BALTIMORE--(BUSINESS WIRE)--WindMIL Therapeutics, a clinical stage company developing Marrow-Infiltrating Lymphocytes (MILs™) for cancer immunotherapy, today announced the completion of a $32.5 ...

PHILADELPHIA and BALTIMORE, April 21, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today ...

PHILADELPHIA and BALTIMORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today ...

PHILADELPHIA and BALTIMORE, May 28, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today ...

TrakCel and WindMIL Therapeutics have formed a partnership to build a custom-configured cellular supply chain tracking and orchestration platform. TrakCel-a software developer for cell and gene ...

BALTIMORE and PHILADELPHIA, Feb. 05, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today ...

WildMil Therapeutics announced that cofounder Kimberly Noonan, Ph.D, MPH, has been named EVP, chief science and technology officer. “It’s an exciting time at WindMil, with the ongoing enrollment of ...

“NextUp” is a weekly NextHealth PHL feature that highlights the local leaders, organizations and research shaping the Greater Philadelphia region’s life sciences ecosystem. Email ccunningham@phillymag ...

PHILADELPHIA and BALTIMORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today ...